A study published today in the journal Nature by researchers at Columbia University described a new medical AI model that they say can accurately predict the activity of genes at the cellular level.
The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.
Quibim, a Spanish startup that’s developing foundational AI models for medical imaging ... for processing multi-omics data (i.e. different types of biological data), for example in clinical ...
A recent industry study of 500+ global decision-makers reveals a compelling insight: successful AI implementation isn't about choosing between different types of AI – it's about understanding ...